Latest GERD Stories

There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease. Clinical Gastroenterology and Hepatology is the official journal of the American Gastroenterological Association (AGA) Institute.GERD is a commonly occurring condition in the U.S., with more...

Patient satisfaction with their medications and the quality of interactions with their doctor reflect the success of gastroesophageal reflux disease (GERD) therapy, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute."Although patient satisfaction is a complex issue, improvements in recognition of GERD can improve management of the disease as well as patient satisfaction with their care...

Gastroesophageal reflux diseases , or GERD, affects about 10 million people in the United States, yet the cause and an unexpected increase in its prevalence over the last three decades remains unexplainable. Now, researchers have discovered that GERD is associated with global alteration of the microbiome in the esophagus. The findings, reported in the August 1, 2009 issue of Gastroenterology, may provide for the foundation for further study of the condition as a microecological disease with...

WILMINGTON, Del., June 2 /PRNewswire-FirstCall/ -- Two studies from AstraZeneca (NYSE: AZN) show that symptomatic gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks(1). NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD. NEXIUM, in a class of drugs...

ST. PAUL, Minn., April 3 /PRNewswire/ -- Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastroesophageal reflux disease (GERD) has commenced a pivotal clinical trial of its LINX(TM) Reflux Management System. The trial, which is being conducted at 15 leading academic and private medical centers in the U.S. and Europe, will evaluate the safety and effectiveness of the LINX System in patients suffering from GERD despite medical therapy. GERD is...

New incisionless, non-invasive procedure treats patients with chronic reflux disease SEATTLE, March 17 /PRNewswire-USNewswire/ -- Northwest Hospital & Medical Center today announced that two surgeons from its medical staff completed the first EsophyX procedure in Washington State on Monday, March 16. EsophyX is a non-invasive, incisionless procedure used to treat gastroesophageal reflux disease, or GERD. The two surgeons, Peter Billing, MD, of Puget Sound Surgical Center and Nicole...

DEERFIELD, Ill., Feb. 23 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that KAPIDEX(TM) (dexlansoprazole) delayed release capsules are now available in pharmacies across the U.S. KAPIDEX, available in 30 mg and 60 mg doses, was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance...

First proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation DEERFIELD, Ill., and OSAKA, Japan, Jan. 30 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX(TM) (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal...

Two non-surgical, non-pharmacological treatments for gastroesophageal reflux disease both appear effective in reducing medication use, U.S. researchers say. GERD -- a condition in which acid from the stomach backs up into the esophagus -- is typically treated first with medications such as proton pump inhibitors. However, it may be difficult for patients to comply with or afford long-term drug therapy, and GERD returns more than 80 percent of the time when medication is discontinued. One...

Two non-surgical, non-pharmacological treatments for gastroesophageal reflux disease (GERD) both appear effective in reducing medication use and improving voice and swallowing symptoms, according to a report in the January issue of Archives of Surgery, one of the JAMA/Archives journals. One type of therapy also appears effective for reducing heartburn and cough, whereas the other may be associated with a reduction in regurgitation.GERD"”a condition in which acid from the stomach backs up...